OS Therapies Incorporated (OSTX)
XASE:OSTX
OSTX Stock Chart & Stats
$1.44
$0.51(10.41%)
At close: 4:00 PM EST
$1.44
$0.51(10.41%)
Day’s Range― - ―
52-Week Range$1.12 - $2.57
Previous CloseN/A
Volume28.07K
Average Volume (3M)444.71K
Market Cap
$49.65M
Enterprise Value-$220.18M
Total Cash (Recent Filing)$269.83M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Apr 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding35,214,350
10 Day Avg. Volume420,306
30 Day Avg. Volume444,714
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.04
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-4.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.00Price Target Upside594.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$12.75M
Bulls Say, Bears Say
Bulls Say
Biomarker-supported EfficacyFDA indication that survival results combined with immune activation biomarker data could support accelerated approval strengthens the case that single-arm study effectiveness may be sufficient for an initial regulatory clearance.
Regulatory EngagementFDA elevation of OST-HER2 interactions to a Type B Pre-BLA meeting signals advancing regulatory engagement and supports planning for a formal biologics license application review.
Regulatory Incentives And FundingOrphan, Fast Track, and Rare Pediatric Disease designations make OST-HER2 eligible for a priority review voucher, creating a potential source of non-dilutive capital to support ongoing development.
Bears Say
Confirmatory Study RequirementsPursuit of accelerated approval is expected to require a confirmatory study, which could delay full approval and impose additional trial costs and resource demands.
OS Therapies Incorporated News
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.12 and its highest was $2.57 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
OS Therapies Incorporated’s market cap is $49.65M.
When is OS Therapies Incorporated’s upcoming earnings report date?
OS Therapies Incorporated’s upcoming earnings report date is Apr 06, 2026 which is in 4 days.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on Nov 14, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.122 by -$0.088.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate is -0.14.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 35,214,350 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.122. Following the earnings report the stock price went down -1.099%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OS Therapies Incorporated Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (594.44% Upside)
$10.00 (594.44% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.90%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
23.48%
Trailing 12-Months
Company Description
OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
OSTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(594.44% Upside)
Technical Analysis
Ownership Overview
18.37% Insiders
1.75% Mutual Funds
1.35% Other Institutional Investors
77.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---